As of the latest Form 4 filed May 20, 2026.
What Accendra Health Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Newest filing first — the 16 most recent filings for ACH.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | 2026-05-18 | Galloway Heath H EVP,General Counsel & CorpSecy | FTax | −1.82K | $2.91 | $5.30K | No | Form 4 ↗ |
| 2026-05-19 | 2026-05-15 | Leon Jonathan A EVP & CFO | FTax | −1.77K | $3.04 | $5.38K | No | Form 4 ↗ |
| 2026-05-19 | 2026-05-15 | Pesicka Edward A President & CEO | FTax | −17.7K | $3.04 | $53.8K | No | Form 4 ↗ |
| 2026-05-19 | 2026-05-15 | Galloway Heath H EVP,General Counsel & CorpSecy | FTax | −966.00 | $3.04 | $2.94K | No | Form 4 ↗ |
| 2026-05-19 | 2026-05-15 | Bernocchi Perry A EVP, Chief Operating Officer | FTax | −7.91K | $3.04 | $24.0K | No | Form 4 ↗ |
| 2026-05-18 | 2026-05-14 | Kline Teresa L. Director | AAward | +31.2K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-18 | 2026-05-14 | Klemash Stephen W Director | AAward | +31.2K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-18 | 2026-05-14 | Gardner-Smith Kenneth Director | AAward | +31.2K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-18 | 2026-05-14 | Beck Mark A Director | AAward | +31.2K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-24 | 2026-03-20 | Pesicka Edward A President & CEO | FTax | −58.9K | $2.03 | $120K | No | Form 4 ↗ |
| 2026-03-24 | 2026-03-20 | Leon Jonathan A EVP & CFO | FTax | −11.3K | $2.03 | $22.9K | No | Form 4 ↗ |
| 2026-03-24 | 2026-03-20 | Bernocchi Perry A EVP, Chief Operating Officer | FTax | −20.8K | $2.03 | $42.3K | No | Form 4 ↗ |
| 2026-03-24 | 2026-03-20 | Galloway Heath H EVP,General Counsel & CorpSecy | FTax | −9.35K | $2.03 | $19.0K | No | Form 4 ↗ |
| 2026-03-10 | 2026-03-09 | Bernocchi Perry A EVP, Chief Operating Officer | AAward | +109K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-10 | 2026-03-09 | Leon Jonathan A EVP & CFO | AAward | +85.1K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-10 | 2026-03-09 | Galloway Heath H EVP,General Counsel & CorpSecy | AAward | +61.4K | $0.00 | $0.00 | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also ACH’s full analysis or the market-wide insider trading feed. The tabs above jump to ACH’s other SEC data.
Source: SEC Form 4 filings for ACH, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.